Press Release
CORRECTING and REPLACING the Not-So-Secret Lives of REAL "Mormon" Wives - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published less than 70 days after the launch of The Secret Lives of Mormon Wives (the Hulu/Disney reality show), The Not-So-Secret Lives of REAL "Mormon" Wives is a first-person book from Cedar Fort that features eight co-authors, each happily married women and mothers who are self-proclaimed devout members of The Church of Jesus Christ of Latter-day Saints, each successful businesswomen and contributors to society in their own right. As such, The Not-So-Secret Lives of REAL "Mormon" Wives has been published by Cedar Fort as a counterpoint to the portrayals of women in the unscripted Hulu/Disney series that have been held-up to the world as examples of Latter-day Saint women, as well as other recent misrepresentations of Latter-day Saints in the media, a book designed to support women, wives, and mothers of faith everywhere and to affirm the reality that no one needs to "Hide their light under a bushel.*" Read More
Press Release
Epomaker Black Friday Sale: Unbelievable Discounts on Premium Keyboards
The world's largest annual shopping event, Black Friday, will soon kick off. Epomaker is thrilled to express its gratitude by offering a host of surprises and discounts, providing even more value and options for everyone during this festive season. Read More
Press Release
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Canalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA Jaguar is attending the December 3-5 Pet Connect conference and is available for NP300 partnership discussions at the event Read More
Press Release
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment Read More
Press Release
Ondas Receives its Latest Purchase Order for the Iron Drone Raider Counter-Drone System from a Major Defense Company
Purchase order to facilitate future orders and deployments of the system with new defense and homeland security customers As a unique AI-integrated interception drone system, the Iron Drone Raider offers a new method for neutralizing hostile drones while minimizing collateral damage Commercially launched last year, the Raider system has been enhanced to meet specific military requirements and has already received orders from leading military and defense organizations Read More
Press Release
First Gas-To-Power Data Centre Connection
HIGHLIGHTS First two modular data centres (MDCs) operated under the Joint Development Agreement (JDA) with Blackhart Technologies are now being populated with first 589 Bitmain S19J Pro (104T) Antminers used for Bitcoin mining (see images overleaf); The first two MDCs are expected to be fully populated with miners over the weekend and connected to Gentech gas fired generators; AXP's focus is to deliver performance reliability from gas-to-power generation to ensure uptime of Bitcoin mining operations. Demonstrating this performance reliability provides the catalyst for commencement of similar operations at two more sites and further expansion thereafter; The Company will keep shareholders updated on operations under the JDA as well as other ongoing field development activities. Read More
Press Release
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) IND enabling studies underway, with Phase I initiation expected in Q425 Webcast and conference call to be held today at 4:30 pm ET Read More
Press Release
